Home >> Proteins >> Recombinant Proteins

Recombinant Proteins(重组蛋白)

Recombinant proteins are a new combination of genes that forms DNA. Recombinant DNA technology allows for the production of wild type and modified human and mammalian proteins at bulk quantities. Recombinant proteins are made from cloned DNA sequences which usually encode an enzyme or protein with known function

Recombinant proteins are made through genetic engineering, also called gene splicing or recombinant DNA technology. By putting human, animal or plant genes into the genetic material of bacteria, mammalian or yeast cells, these microorganisms can be used as factories or producers to make proteins for medical, academic and research uses.

A vector is simply a tool for manipulating DNA and can be viewed as a "transport vehicle" for the production of proteins from specific DNA sequences cloned into them. Purification and expression of a protein can sometimes be quite complicated & time-consuming, therefore an additional tag is used in addition to the specific DNA sequence which will facilitate the purification & expresion of the recombinant protein.

Recombinant Proteins are proteins that their DNA that has been created artificially. DNA from 2 or more sources which is incorporated into a single recombinant molecule. The DNA is first treated with restriction endonuclease enzyme which the ends of the cut have an overhanging piece of single-stranded DNA. These are called "sticky ends" because they are able to base pair with any DNA molecule containing the complementary sticky end. DNA ligase covalently links the two strands into 1 recombinant DNA molecule.

Recombinant DNA molecule must be replicated many times to provide material for analysis & sequencing. Producing many identical copies of the same recombinant DNA molecule is called cloning. Cloning is done in vitro, by a process called the polymerase chain reaction (PCR). Cloning in vivo can be done in unicellular microbessuch as E. coli, unicellular eukaryotes like yeast and in mammalian cells grown in tissue culture.

Recombinant DNA must be taken up by the cell in a form in which it can be replicated and expressed. This is achieved by incorporating the DNA in a vector. A number of viruses (both bacterial and of mammalian cells) can serve as vectors.

Recombinant DNA is also sometimes referred to as chimera. When combining two or more different strands of DNA.There are 3 different methods by which Recombinant DNA is made. 1. Transformation, 2. Phage-Transfection 3.Yeast, Plant & Mammalian Transformation. When using the method of transformation one needs to select a piece of DNA to be inserted into a vector, cut a piece of DNA with a restriction enzyme and ligate the DNA insert into the vector with DNA Ligase. The insert contains a selectable marker which allows for identification of recombinant molecules. An antibiotic marker is used in order to cause death for a host cell which does not contain the vector when exposed to a certain antibiotic.

Trasnformation is the insertion of the vector into the host cell. The host cells are prepared to take up the foreign DNA. Selectable markers are used for antibiotic resistance, color changes, or any other characteristic which can distinguish transformed hosts from untransformed hosts. Yeast, Plant & Mammalian Transformation is done by micro-injecting the DNA into the nucleus of the cell being transformed. Phage-Transfection process, is equivalent to transformation except for the fact that phage lambda or MI3 is used instead of bacteria.

These phages produce plaques which contain recombinant proteins which can be easily distinguished from the non-recombinant proteins by various selection methods.

Significant amounts of recombinant protein are produced by the host only when expression genes are added. The Protein’s expression depends on the genes which surround the DNA of interest, this collection of genes act as signals which provide instructions for the transcription and translation of the DNA of interest by the cell. These signals include the promoter, ribosome binding site, and terminator.

The recombinant DNA is inserted into expression vectors which contain the promoter, ribosome binding site, and terminator.

In prokaryotic systems, the promoter, ribosome binding site, and terminator have to be from the same host since the bacteria is unlikely to understand the signals of human promoters and terminators. The designated gene must not contain human introns since the bacteria does not recognize it and this results in premature termination, and the recombinant protein may not be processed correctly, be folded correctly, or may even be degraded.

The peptide sequence can be added as an extension at the N-terminal. Researchers can select the specific purification system which they would like to use. The unique vectors available contain several features needed for the production of bulk quantities of the target protein. The peptide sequence is usually placed in the vector so that it is designed to be a point of attack for a specific protease. Thus, after the recombinant protein is expressed and extracted from bacteria, specific peptide extension can be used to purify the protein and subsequently removed from the target protein to generate a nearly natural sequence on the final product.

6 or more consistent Histidine residues act as a metal binding site for recombinant protein purification and expression. The hexa-His sequence is called a His-Tag sequence which can be placed on the N-terminal of a target protein by using vectors from various commercial molecular biology companies. The His-Tag contains a cleavage site for a specific protease. His-Tag recombinant proteins are purified by Metal Chelate Affinity Chromatography such as nickel ion columns that are used as the heavy metal ion and the His-Tag protein is eluted from the metal-chelate column with Histidine or imidazole. Then the purified His-Tag protein is treated with the specific protease to cleave off the His-Tag or not if the tag doesn’t affect the active site of the protein.

Proteins have metal binding sites which can be used for the purification of recombinant and natural proteins. This type of purification is rather simple when using a gel bead which is covalently modified so that it displays a chelator group for binding a heavy metal ion like Ni2+ or Zn2+. The chelating group on the gel bead contains a small amount of the ligands needed to hold the metal ion. So when the protein’s metal binding site finds the heavy metal, it will bind by providing the ligands from its metal binding site to attach to the metal ion displayed on the chelator location of the gel bead. This purification method is quite identical to affinity chromatography when purifying metal-binding class of proteins.

Products for  Recombinant Proteins

  1. Cat.No. 产品名称 Information
  2. GP26226 C5 Human Human Complement C5 produced in Human plasma having a molecular mass of 190 kDa
  3. GP26225 C4b Human Human Complement C4b produced in Human plasma is a glycosylated polypeptide chain containing 3 disulfide-linked chains and having a molecular mass of 195 kDa
  4. GP26224 C4a Human Human Complement C4a produced in Human plasma having a molecular mass of 8,759 Dalton
  5. GP26223 C4 Human Human Complement C4 produced in Human plasma having a molecular mass of 205 kDa
  6. GP26222 C4BP Human C4BP Human produced in Human Plasma having a molecular mass of 540 kDa
  7. GP26221 C3d Human Human Complement C3d produced in Human plasma having a molecular mass of 33
  8. GP26220 C3b Rat Rat Complement C3b produced in Rat plasma having a molecular weight of 175kDa
  9. GP26219 C3b Mouse Mouse Complement C3b produced in Mouse plasma having a molecular weight of 175kDa
  10. GP26218 C3b Human Human Complement C3b produced in Human plasma having a molecular mass of 176 kDa
  11. GP26217 C3a Human

    Human Complement C3a produced in Human plasma is an non glycosylated polypeptide chain containing 77 amino acids having a molecular weight of 9,089 daltons

  12. GP26216 C3 Rabbit Rabbit Complement C3 produced in Rabbit plasma having a molecular mass of 185 kDa
  13. GP26215 C3 Rat Rat Complement C3 produced in Rat plasma having a molecular weight of 187kDa
  14. GP26214 C3 Mouse Mouse Complement C3 produced in Mouse plasma having a molecular weight of 185kDa
  15. GP26213 C3 Human Human Complement C3 produced in Human plasma having a molecular mass of 185 kDa
  16. GP26212 C2 Human Human Complement C2 produced in Human plasma having a molecular mass of 93 kDa
  17. GP26211 C1Q Rat Rat Complement C1Q produced in Rat plasma having a molecular weight of 400kDa
  18. GP26210 C1Q Mouse Mouse Complement C1Q produced in Mouse plasma having a molecular weight of 439
  19. GP26209 C1q Human, Liquid Human Complement Component C1q produced in Human plasma having a molecular mass of 410 kDa
  20. GP26204 Anaplasma OmpA Anaplasma OmpA produced in E
  21. GP26174 POR Human, Active POR produced in Sf9 Baculovirus cells is a single,glycosylated polypeptide chain containing 686 amino acids (1-680a
  22. GP26132 C1S Human Human Complement C1s produced in Human plasma having a molecular mass of 86 kDa
  23. GP26131 C1R Human Human Complement C1r produced in Human plasma having a molecular mass of 92 kDa
  24. GC25991 tetrathiomolybdate Tetrathiomolybdate (TM) is used in the clinic for the treatment of Wilson's disease by inducing dimerization of the metal-binding domain of the cellular copper efflux protein ATP7B (WLN4) through a unique sulfur-bridged Mo2S6O2 cluster.
  25. GC25935 Simufilam dihydrochloride Simufilam (PTI-125) Dihydrochloride is a small molecule modulator that preferentially binds altered FLNA and restores its native conformation, restoring receptor and synaptic activities and reducing its α7nAChR/TLR4 associations and downstream pathologies.
  26. GC68416 RAD51-IN-3 RAD51-IN-3 是一种 RAD51 抑制剂,详细信息请参考专利 WO2019051465A1 的化合物 Example 66A。
  27. GC68390 α5β1 integrin agonist-1 α5β1 integrin agonist-1 作为 α5β1 integrin 激动剂,能够选择性地将 5-FU 输送到肿瘤细胞中,成功地导致肿瘤细胞死亡。
  28. GC68283 Etrolizumab Etrolizumab (rhuMAb Beta7) 是一种肠道选择性抗-β7 整合素单克隆抗体。Etrolizuma b是针对 α4β7 和 αEβ7 整合素的 β7 亚基的特异性靶向药物。Etrolizumab 可用于炎症性肠病 (IBD) 的研究。
  29. GC67888 RAD51-IN-5 RAD51-IN-5 是一种有效的 RAD51 抑制剂。RAD51 是一种真核生物基因。RAD51-IN-5 具有研究线粒体缺陷病症的潜力 (摘自专利 WO2021164746A1,化合物 3)。
  30. GC67778 Sirtuin modulator 3 Sirtuin modulator 3 (compound 129) 是一种 N -苯基苯甲酰胺衍生物,作为 Sirtuin 调制剂。
  31. GC67708 PLN-1474 PLN-1474 (compound 1) 是具有口服活性的,选择性的 avß1 整合素抑制剂,IC50 值 <50 nM。PLN-1474 在肝纤维化小鼠模型中显著降低肝脏 pSMAD3/SMAD3 水平、肝脏胶原蛋白基因表达和肝脏 OHP 浓度。PLN-1474 可用于预防、延缓或治疗纤维化或肝硬化疾病或紊乱的研究。
  32. GC52332 Arimoclomol A co-inducer of heat shock proteins
  33. GC52283 L-Cysteine-15N-d3 An internal standard for the quantification of L-cysteine
  34. GC66026 SIRT2-IN-9 SIRT2-IN-9 (compound 12) 是 SRIT2 的选择性抑制剂,IC50 值为 1.3 μM。SIRT2-IN-9 抑制 MCF-7 乳腺癌细胞的增殖活性。SIRT2-IN-9 可用于癌症的研究。
  35. GC65935 CAM833 CAM833 是一种有效的抑制 BRCA2 和 RAD51 之间相互作用的正位抑制剂,对 ChimRAD51 蛋白的 Kd 为 366 nM。 CAM833 也抑制 RAD51 的寡聚。
  36. GC65909 Bexotegrast Bexotegrast 是 αΝβ6 整合素的有效抑制剂。Bexotegrast 可用于研究特发性肺纤维化 (IPF) 和非特异性间质性肺炎 (NSIP) 等纤维化 (信息摘自专利 WO2020210404A1,compound 5)。
  37. GC52173 N-desmethyl-Doxylamine (succinate) A metabolite of doxylamine
  38. GC65597 Abciximab Abciximab (C7E3) 是一种小鼠/人嵌合单克隆抗体,是一种糖蛋白 IIb/IIIa(glycoprotein IIb/IIIa)抑制剂。 Abciximab 通过与糖蛋白 IIb/IIIa、vitronectin 和 Mac-1 受体结合抑制血小板聚集和白细胞粘附。
  39. GC65581 MIND4-19 MIND4-19 是一种有效的 SIRT2 抑制剂,IC50 为 7.0 μM。MIND4-19 可用于亨廷顿氏舞蹈症 (Huntington's disease) 的研究。
  40. GC65455 c(phg-isoDGR-(NMe)k) c(phg-isoDGR-(NMe)k) 是有效选择性的 α5β1 整合素 配体,IC50 为 2.9 nM。
  41. GC65383 RAD51-IN-2 RAD51-IN-2 (化合物 example 67A) 是一种 RAD51 抑制剂,详细信息请参考专利文献 WO2019/051465A1。
  42. GC65322 FABPs ligand 6 FABPs ligand 6 (MF6) 是一种 FABP5 和 FABP7 抑制剂,KD 值分别为 874 nM 和 20 nM。FABPs ligand 6 可用于多发性硬化症的研究。
  43. GC65030 Sirtuin modulator 2 Sirtuin modulator 2 (Compound 132) 是一种 sirtuin 调节剂,ED50 不超过 50 μM。
  44. GC65019 SRT 1460 SRT-1460 is a potent and selective activator of Sirtuin 1 (SIRT1) with EC1.5 of 2.9 μM. SRT-1460 reduces cell viability and growth of pancreatic cancer cells and induces apoptosis.
  45. GC64946 SRT 2183 SRT2183 is a small-molecule activator of the sirtuin subtype SIRT1, currently being developed by Sirtris Pharmaceuticals.
  46. GC64932 αvβ5 integrin-IN-1 αvβ5 integrin-IN-1 是第一个有效和选择性 αvβ5 整合素抑制剂(pIC50 = 8.2)。
  47. GC64575 Et-29 Et-29 是一种有效的,选择性的 SIRT5 抑制剂 (Ki=40 nM)。
  48. GC64571 Sibrafiban Sibrafiban (RO 48-3657) 是一种 Ro 44-3888 的具有口服活性的,非肽,双重前药,是一种选择性的糖蛋白 IIb/IIIa 受体 (glycoprotein IIb/IIIa receptor) 拮抗剂。Sibrafiban 可抑制血小板聚集。
  49. GC64527 ADTL-SA1215 ADTL-SA1215 是一种调节三阴性乳腺癌自噬的特异性 SIRT3 小分子激活剂。
  50. GC52105 Montelukast A CysLT1 receptor antagonist
  51. GC52088 Methylchloroisothiazolinone (hydrochloride) A biocide

Items 101 to 150 of 2617 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction